BioSpace News Archive

Industry professionals and community members are invited to read and attend a conversation about “Caste: The Origins of Our Discontents” by Isabel Wilkerson

Iterative Scopes, a leading Artificial Intelligence in Gastroenterology provider, today announced the expansion of its world class Scientific Advisory Board with experts in the field of Artificial Intelligence (AI) and IBD.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a Research Agreement with the University of Cincinnati Research Institute (“UCRI”) to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan.

Tree of Knowledge International Inc. (CSE:TOKI) (“TOKI” or the “Company”) is pleased to provide the following update as to the business and operations of TOKI. As previously announced, the Board has determined May 19, 2021 as the date on which it plans to hold the annual general meeting of the Company.

The COVID-19 Exposure Notification App Advisory Council was established to ensure the COVID Alert app meets the highest standards in public health outcomes, privacy and technology.

Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel TNF Superfamily antagonist antibodies, announced today that the company has completed $10 M Series A/A1 preferred stock financing. Investors in the Series A preferred stock financing include BeiGene, Ltd., along with undisclosed private investors and prior investors Hatteras Venture Partners and EGP Investments

GI OnDEMAND ®, gastroenterology’s leading multidisciplinary virtual integrated care platform today announced a partnership with Ambry Genetics®, a leading clinical genetic testing company, to integrate online genetic counseling and testing services into gastroenterology practices nationwide

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the Investor Summit Group’s Q1 Virtual Summit, which is being held from March 23th-25th.

Venarum Medical announced receipt of a Phase I SBIR Grant award for development of K9-ICT: A Novel Urethral Valve Treatment for Canine Urinary Incontinence.

ContraFect Corporation, a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, announced that it has commenced an underwritten public offering of shares of its common stock.